Strategic Client Partner, US

The role

You will drive revenue growth by managing the full lifecycle of a portfolio of top 50 global pharma enterprise customers. You will act as a trusted advisor to existing and target clients to identify business challenges and sell the Causaly Cloud platform.

What you will do

• Become a trusted advisor in the AI Pharma sector to existing and target Causaly clients
• Leverage existing industry network to open discussions and get customer insights
• Establish relationships at senior call points in Top 50 Pharma
• Drive new business for Causaly Cloud platform solution across North America
• Understand assigned clients strategic goals and decision-making structures
• Liaise with Product to refine Product Market Messaging
• Become a champion for the Causaly Platform
• Orchestrate resources internally and externally throughout the sales process
• Communicate account status to executive Causaly management

Required qualifications

• Strategy consulting background in Life Sciences at a top-tier or specialist life sciences consultancy or in-house strategy function of a major pharma company
• Progression to Engagement Manager level or above, or equivalent grade
• Track record of owning senior client relationships and leading complex, multi-stakeholder engagements with pharma clients
• Experience engaging with scientific, technical and economic buyers and decision-makers up to C-Suite in global 30 Pharma
• Consultative selling skills
• Experience selling into Big Pharma & Biotech space
• Ability to work in partnership with Strategic Account Executives
• Experience leading strategic, long-term sales cycles within the biopharma sector
• Strong presenter, both in person and virtually

Benefits

• Competitive compensation package
• Personal development budget
• Individual wellbeing budget
• Your birthday off!
• Unlimited time off
• 12 weeks paid parental leave (after 6 months)

About the company

Causaly is building an AI-powered biomedical knowledge platform to help researchers discover and interpret evidence from scientific publications and other data sources. The company is backed by investors including ICONIQ, Index Ventures, Pentech, and Marathon.